abstract |
The present invention relates to the formulation of anti-BAFFR antibodies into liquid formulations comprising high concentrations of antibody active ingredients for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition can include one or more sugars, buffers, surfactants, and/or free amino acids. |